Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia

NCT00281918 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00281918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00281918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2003
Completion date
October 31, 2011
Enrollment
817 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia